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Purpose: Although transrectal ultrasound-guided prostate biopsy is useful for diagnos-
ing prostate cancer, it is a painful procedure. There are many methods for providing 
pain relief and for treating discomfort during the procedure, but occasionally these are 
reported to be of limited use. We aimed to evaluate the value and safety of mid-
azolam-induced anesthetic transrectal ultrasound-guided prostate biopsy. 
Materials and Methods: From August 2008 to December 2009, 104 male patients, who 
were examined with transrectal ultrasound-guided prostate 12-core biopsy, were ran-
domly assigned to two groups. Group 1 (n=51) received ketorolac (Tarasyn
Ⓡ) 30 mg. 
Group 2 (n=53) was treated with midazolam (Dormicum
Ⓡ) 3 mg, which was increased 
to 5 mg if necessary. Immediately after the procedure, the patients were asked to rate 
their comfort level by using a 10-point visual analog self-assessment pain scale.
Results: The pain scale in group 2 was significantly lower than that in group 1 (p＜0.05). 
The patients assigned to group 2 experienced no side-effects from midazolam and were 
more satisfied than the patients in group 1 (p＜0.05).
Conclusions: Midazolam anesthesia relieves pain effectively, and the patient’s sat-
isfaction is better than with conventional transrectal ultrasound-guided prostate 
biopsy. Midazolam-induced anesthetic transrectal ultrasound-guided prostate biopsy 
is useful and safe.
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INTRODUCTION
Transrectal ultrasound-guided prostate biopsy is routinely 
done to diagnose the absence or presence of malignancy. 
However, with 10 to 12 prostatic cores now being the stand-
ard, the procedure can be painful unless adequate analge-
sia is provided. Although a wide variety of anesthetic tech-
niques are available for transrectal ultrasound-guided 
prostate biopsy, including rectal administration of lido-
caine gel, periprostatic nerve blocks, intravenous propofol, 
and narcotic intramuscular premedication, these methods 
may not optimally prevent or relieve pain. 
　Midazolam has been the most widely used sedative pre-
medication because of its short half-life, faster onset of se-
dation, and excellent sedative hypnotic effect without any 
significant side-effects, such as vasculitis. Midazolam is al-
so associated with strong anterograde amnesia, and with 
usage of flumazenil as an antagonist, the side effects are 
easily treated [1-3]. This study was performed to evaluate 
the value and safety of midazolam anesthesia during trans-
rectal ultrasound-guided prostate biopsy. 
MATERIALS AND METHODS
From August 2008 to December 2009, 104 patients under-
went a 12-core prostate biopsy. Of the 104 patients, 51 pa-
tients (group 1) were randomly assigned to prostate biopsy 
with 30 mg of IM ketorolac (Tarasyn
Ⓡ) and 53 patients Korean J Urol 2011;52:216-220
Value of Midazolam Anesthesia for Prostate Biopsy 217
TABLE 1. Sedation responses of patients with midazolam-in-
duced anesthetic prostate biopsy by sedation scale
Sedation 
scale
No. of 
patients
No response to shaking 1   0
Responds only to shaking 2   6
Responds only to name call loudly 3 47
Lethargic response to name spoken in a
normal tone
4  0
Responds readily to name spoken in a 
normal tone
5  0
Total 53
0123456789 1 0
FIG. 1. Pain score was evaluated with a visual analog scale. A pa-
tient is asked to rate his pain on a scale of 1-10. Rating of 1 repre-
sents mild discomfort from time to time, and a 10 is so severe that
a trip to the emergency room for relief is required. The degree of
pain was interpreted as none (0), mild (1-3), moderate (4-6), severe
(7-9), and intolerable (10).
TABLE 2. Recovery test before and after prostate biopsy with the scale of the Mini Mental State Examination
Category
Possible 
points
Description
Orientation to time 5 From broadest to most narrow. Orientation to time has been correlated with future decline.
Orientation to place 5 From broadest to most narrow. This is sometimes narrowed down to streets, and sometimes to floor.
Registration 3 Repeating named prompts
Attention and 
calculation
5 Serial sevens, or spelling "W-O-R-L-D" backwards. It has been suggested that serial sevens may be
more appropriate in a population where English is not the first language. 
Recall 3 Registration recall
Language 2 Name a pencil and a watch
Repetition 1 Speaking back a phrase
Complex commands 6 Varies. Can involve drawing figure shown.
(group 2) were given 3-5 mg of midazolam IV (Dormicum
Ⓡ). 
Each subject provided informed consent and this study was 
approved by our medical center’s institutional review board.
　The indications for prostate biopsy were an abnormal 
prostate on digital rectal examination and/or elevated se-
rum prostate-specific antigen (PSA) ≥4 ng/ml. The pa-
tients ranged in age from 40 to 86 years (mean, 66.9±9.3 
years). Subjects who had previous prostate biopsy, severe 
cardiovascular disease, pulmonary disease, bleeding hem-
orrhoids, acute anal fissure, or a history of chronic alcohol 
or drug abuse were not included in this study. We also ex-
cluded subjects taking medications such as erythromycin, 
verapamil, diltiazem, itraconazole, and ketoconazole, 
which can have drug interactions specifically with the ben-
zodiazepine class. Anticoagulation or aspirin therapy was 
stopped 1 week before the biopsy and the patients received 
a glycerin enema before the procedure. 
　With the patients in the left lateral decubitus position, 
a digital rectal examination was performed and the rectum 
was cleaned with a Betadine gauze pack. The urologist per-
formed all prostate biopsies under ultrasound guidance by 
using a Medison SA-6000 machine with a 6.5 MHz biplane 
transrectal probe during longitudinal scanning by using an 
automated biopsy gun with a disposable 18 gauge biopsy 
needle. A Betadine pack was kept for approximately 6 
hours at the end of the procedure. The patients in group 2 
were instructed to avoid consuming nicotine, alcohol, and 
caffeinated beverages for at least 12 hours before prostatic 
biopsy to maximize the likelihood that they would be able 
to fall asleep. A nurse intravenously administered mid-
azolam to the subjects at doses of 3 to 5 mg. The initial intra-
venous dose was 3 mg (no more than 0.05 mg/kg) given slow-
ly over at least 2 min, with titration to the desired level of 
sedation. An intravenous dose of 0.02 to 0.03 mg/kg was re-
peated at 2-min intervals while the appropriate level of se-
dation was continually monitored. A total intravenous dose 
of more than 5 mg was not required for any examinations. 
At the end of the procedure, we gave an intravenous in-
jection of flumazenil to facilitate rapid recovery from 
sedation.
　The sedation scale was measured after stimulating the 
patient (i.e., conversing with the patient or shaking the pa-
tient awake). The responses were measured and divided 
according to 5 stages (Table 1). Prostate biopsy was per-
formed when the stage was greater than 3 [4]. After admin-
istration of midazolam, the presence of complications or 
side-effects to include apnea, oxygen desaturation, auto-
nomic movement, chest pain, arrhythmia, injection in situ 
pain, and phlebitis were also assessed. The subjects were 
discharged once they fully recovered orientation of time 
and space in the setting of normal vital signs. Immediately 
after the procedure, the patients were asked to rate their 
comfort level by using a 10-point visual linear analog 
self-assessment pain scale (Fig. 1) [5]. The degree of pain 
was interpreted as none (0), mild (1-3), moderate (4-6), se-
vere (7-9), and intolerable (10), accordingly. They were also 
asked whether their pain control method was satisfactory 
and whether they would be willing to undergo a repeat 
biopsy. 
　Recovery from sedation was assessed by using the Mini- Korean J Urol 2011;52:216-220
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TABLE 3. Characteristics of the patients 
Mean±SD
Group 1 
(n=51)
Group 2 
(n=53)
p-value
Age (yr) 67.1±9.3 66.4±9.2 ＞0.05
Weight (kg)   64.9±10.1 67.4±8.2 ＞0.05
Body mass index (kg/m
2) 24.3±2.7 23.7±3.3 ＞0.05
Prostate-specific antigen
 (ng/ml)
    48.9±111.8 21.4±280.6 ＞0.05
Prostate volume (cc)   41.4±15.8 44.5±21.8 ＞0.05
Group 1: ketorolac group, Group 2: midazolam-induced anesthetic
group
TABLE 4. Comparison of parameters between before and after 
midazolam injection
Goup 2 (n=53)
p-value
Pre-I Post-I
BP (mean±SD)
　Systolic    120±18.8      116±18.5 ＜0.05
　Diastolic       82±11.7        76±10.5 ＞0.05
PR (mean±SD)      73±10.1        73±10.4 ＞0.05
MMSE 26.04±2.36 25.95±2.0   ＞0.05*
Group 2: midazolam-induced anesthetic group, BP: blood pressure 
(mmHg), PR: pulse rate, Pre-I: before midazolam injection, Post-I: 
after midazolam injection, MMSE: Mini-Mental State Examination
FIG. 2. Distribution of the cases in each group in regard th the 
degree of discomfort.
FIG. 3. Comparision of the groups for mean pain scale and satis-
faction percentil.
Mental State Examination (MMSE) (Table 2) [6]. The 
MMSE was translated into and cross-culturally validated 
for the Korean language (K-MMSE) [7].The survey re-
sponses were coded and analyzed by using descriptive sta-
tistics, which are reported as medians with 5-95th percen-
tiles. The statistical analysis was carried out by using the 
Student’s t-test or the paired t-test. Statistical significance 
was defined as a p-value less than 0.05. The statistical anal-
yses were performed by using SPSS ver. 15.0 (SPSS Inc., 
Chicago, IL, USA). 
RESULTS
There were no significant differences in age, weight, body 
mass index, PSA, or prostate volume among the groups 
(Table 3). The differences in the pain scores were statisti-
cally significant (p＜0.05). In group 1, none or mild degrees 
of discomfort were expressed by 7 (13.7%) cases and severe 
or intolerable discomfort by 19 (37.2%), respectively. In 
group 2, none or mild degrees of discomfort were reported 
by 31 (58.5%) cases, whereas severe or intolerable dis-
comfort occurred in only 1 (1.8%) patient (Fig. 2). In group 
1, satisfaction with the pain control methods was noted in 
11 (21.5%) cases and willingness to undergo a repeat biopsy 
by using the same pain control measures was noted in 10 
(19.6%) cases. Satisfaction and willingness were higher in 
group 2 than in group 1 (75.5% and 60.3%, respectively, p＜ 
0.05) (Fig. 3). 
　The mean midazolam usage dose was 3.94 mg, and the 
mean time from injection to sedation was 5.1 minutes. We 
did not detect the aforementioned side-effects of mid-
azolam in patients randomly assigned to the midazolam 
groups. Mild headache (4 patients), nausea (3), paradoxical 
rage (1), and transient delirium (1) were noted but sponta-
neously disappeared without treatment. All changes in 
blood pressure and pulse rate were below 20% of baseline 
values, and no patients were treated owing to changes in 
vital signs. The differences in the MMSE score were not 
statistically significant (p＞0.05) (Table 4).
DISCUSSION
Transrectal ultrasound-guided prostate biopsy is generally 
performed on an outpatient basis given its low complica-
tion rates and minimal to no need for anesthesia. However, 
a considerable degree of patient discomfort has been re-
ported in the literature [8,9]. Pain during prostate biopsy 
and the anticipating anxiety regarding the procedure may 
cause unfavorable results or may influence a patient’s deci-
sion to undergo a repeat biopsy. Although the application 
of local anesthesia is somewhat effective, pain may not be 
optimally relieved during prostate biopsy in some patients. Korean J Urol 2011;52:216-220
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FIG. 4. Distribution of the cases in regard to the degree of cogni-
tion Mini-Mental State Examination (MMSE).
TABLE 5. Additional cost for midazolam-induced anesthesia 
under health insurance coverage
Midazolam
O2  saturation monitoring
Intravenous injection fee
ECG monitoring
Blood pressure monitoring
$0.20
$1.07
$0.21
$1.73
$1.93
Total cost $5.14
ECG: electrocardiogram
Given the general consensus regarding the need for some 
form of anesthesia, establishment of standard methods 
during transrectal ultrasound-guided prostate biopsy has 
been prompted.
　Midazolam is a water-soluble benzodiazepine with a 
short half-life. Midazolam provides sedation/anesthetic ef-
fects but without any analgesic effects. The major advan-
tages of midazolam over diazepam include a shorter dura-
tion of action, profound anterograde amnesia, and better 
local tolerance, such as less burning on injection and lack 
of postoperative phlebitis [3,10,11]. Midazolam has a high 
affinity for the benzodiazepine receptor in the central nerv-
ous system, with in vitro data demonstrating that it has ap-
proximately twice the affinity of diazepam [12,13]. The 
amino acid neurotransmitter gamma-aminobutyric acid 
(GABA) must be present for the benzodiazepine to elicit a 
response and for benzodiazepines enhance the inhibitory 
action of GABA [14,15]. The actions of benzodiazepines do 
not involve the synthesis, release, or altered metabolism 
of GABA, but rather potentiate the inhibitory actions of 
GABA by augmenting the flow of chloride ions through ion 
channels. The increased flux of chloride ions into the cell 
decreases the ability of the cell to initiate an action poten-
tial [16]. Midazolam is a sedative drug with amnesic pro-
perties. Previous studies have found that anterograde, but 
not retrograde, amnesia can be demonstrated with mid-
azolam [17-19]. However, midazolam produces the imme-
diate onset of anterograde amnesia in patients [20]. This 
may be useful in preventing the explicit recall of perioper-
ative events. Because the onset of and the recovery from 
sedation is rapid and the risk of respiratory and cardio-
vascular depression is less for midazolam in comparison 
with the other agents used for sedation, it is the preferred 
agent for intervention procedures [12]. In addition, it can 
safely be used in patients suffering from coronary artery 
disease or hypertension [21].
　In this study, the patients who received midazolam had 
both significantly less pain than did the ketorolac group 
and more satisfied pain control. Also, 32 patients (60.3%) 
in the midazolam group were willing to undergo a future 
biopsy if required. The mean pain score in group 1, which 
received ketorolac, was 6.7, which is within the range of 
moderate to severe discomfort. The mean score of 2.7 calcu-
lated for group 2 was within the range of a mild degree of 
discomfort. Prostate biopsy has now become common with 
the increased use of PSA, and more biopsy cores are taken 
to increase the cancer detection rate. It has been reported 
that rectal administration of lidocaine has no impact on the 
tolerance of prostatic biopsy [22]. Although a periprostatic 
nerve block has been widely reported to be highly efficient, 
it is worthy to note that no significant difference or only bor-
derline improvement in pain scores was detected in several 
recent studies, which suggests that pain relief with peri-
prostatic nerve block is not as effective as previously sug-
gested [23,24]. Irani and colleagues also reported that 
there was ineffective pain control, with 19% not agreeing 
to undergo prostate re-biopsy without some form of anes-
thesia [25]. There is no doubt that it is of great importance 
to establish a method of anesthesia that would improve pa-
tient tolerance to the procedure. In turn, improved pain 
control will likely increase patient agreement for re-biopsy 
when needed for cancer detection. 
　The administration of midazolam and the routine non-
invasive monitoring was performed by an anesthesiologist 
in several studies [26,27]. In our study, blood pressure and 
pulse rate did not change significantly during the proce-
dure and no patients had respiratory depression or hypo-
tension. Based on our experience, it is not necessary to have 
monitoring performed by an anesthesiologist. However, 
monitoring should be performed by an appropriately trained 
nurse or physician.
　The use of midazolam anesthesia may increase the pro-
cedure costs associated with a prostate biopsy. In the pres-
ent study, the total cost per procedure was higher ($5.14) 
for the midazolam anesthesia group, but the majority of the 
cost was covered by Korean health insurance. The additional 
cost for midazolam-induced anesthesia under health in-
surance coverage is shown in Table 5.
　Overall, 40 patients had a baseline MMSE score of ≥25 
(normal), 13 had an MMSE score of 21-24 (mild), and no pa-
tients had an MMSE score of ≤20 (moderate to severe). 
After prostate biopsy, an MMSE score of ≥25 was found 
in 39 patients, an MMSE score of 21-24 was found in 14 pa-
tients, and an MMSE score of ≤20 was not found (Fig. 4). 
The difference in the MMSE score was not significant after Korean J Urol 2011;52:216-220
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the midazolam anesthesia and there was no cognitive 
change to moderate or severe (score below 20). Side effects 
of midazolam administration have been seen in some pa-
tients [28,29]. However, no patients in this study had to be 
treated for side effects after midazolam anesthesia. Our 
study indicates that midazolam anesthesia during pros-
tate biopsy is well tolerated and is associated with no or 
minimal discomfort.
CONCLUSIONS
The use of midazolam is a very simple technique that pro-
vides adequate analgesia during transrectal ultrasound- 
guided prostate biopsy. In addition, patient satisfaction is 
improved during conventional transrectal ultrasound- 
guided prostate biopsy. The use of midazolam is non-
invasive and free of any local complications or systemic side 
effects. Midazolam reduced pain sensation significantly. 
Midazolam-induced anesthetic transrectal ultrasound- 
guided prostate biopsy is a safe and useful method.
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